HER2-TARGETED THERAPIES

This retrospective cohort study of women who received more than 12 months of trastuzumab for metastatic HER2-positive breast cancer noted that patients who developed cardiotoxicity were more likely to receive third-line cancer treatments and had lower final left ventricular ejection fraction than patients without. The cumulative incidence of cardiotoxicity was 35%. Identifying a cardiac care gap, the authors noted that many of the women with cardiotoxicity were not referred to cardiology.